S6 Ep14: How a Cancer Journey Connects Oncologist to His Patients
Cancer Horizons25 Jan 2024

S6 Ep14: How a Cancer Journey Connects Oncologist to His Patients

Often, receiving a cancer diagnosis can require a crash course in oncology that few patients ever expected to take.

For colorectal cancer specialist Dr. Dustin Deming, the ACI/Schwenn Family associate professor in the division of hematology, medical oncology and palliative care at UW School of Medicine and Public Health, a diagnosis of rectal cancer two weeks after receiving his first faculty appointment required an education of a different sort.

Deming, a gastrointestinal oncologist and laboratory researcher for UW Health | Carbone Cancer Center, told CURE®, needed to learn how to be a patient.

“For me, the crash course was in being able to allow my medical friends to be my doctors,” said Deming. “So, that was the part that I really had to wrap my head around. I knew what we needed to do. I knew I knew what I was about to go through. But I hadn't sat in the patient chair before. And so, the crash course that I had to enter was the crash course in what it's like to be a patient.”

Deming was 31 at the time of his diagnosis in 2012, married and with a 12-week-old daughter who he’d brought to his colonoscopy appointment. Treatment with surgery, chemotherapy and radiation followed, with Deming working as he was able to do so.

While colorectal cancer is the fourth most common cancer diagnosis in the United States, only 2% of new cases occur in patients ages 20 to 34, with the majority of cases (25.5%) occurring in patients ages 65 to 74, according to the National Cancer Institute.

“It’s obviously extremely ironic, and (was) potentially life-shattering at the time,” Deming said. “You know, when I was diagnosed, I had a 12-week-old daughter who came to the colonoscopy with me. Getting that kind of news at 31, I don't think anybody's prepared for. Having been a colon cancer doctor and researcher was helpful in that it provided me in insight into what we needed to do. But it was also terrifying, in that I knew all the dirty secrets.”

After being cancer-free for eight and a half years, Deming experienced a recurrence in 2020. He received further chemotherapy, radiation and surgery, followed by a second recurrence about a year later that was treated with surgery and chemotherapy. Approximately 10 months after his latest surgery, he has no evidence of cancer.
Dustin spoke with CURE’s “Cancer Horizons” podcast about his cancer journey, the connections it’s created with his patients and his continuing dedication to treating others.

“Having been a patient myself, I feel like — now, I don't know how it feels for each individual patient, but I know how it feels for me — I know how it feels to hear the ‘cancer’ word, I know how it feels to have to go through chemo, radiation and multiple surgeries,” Deming said. “So, every time I meet a patient for the first time, I sit down and tell the patients kind of where I've been so that they know where I'm coming from and also (to) make sure that they know that I now get it and that I'm actually truly honored to be part of the team helping take care of them.


“I know what it means to trust oncologists with your care, and I'm so glad that I'm here to be able to help more patients.”


For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.



Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(295)

S7 Ep2: Breaking Down Metastatic Triple-Negative Breast Cancer Treatments

S7 Ep2: Breaking Down Metastatic Triple-Negative Breast Cancer Treatments

CURE sat down with Dr. Natalie S. Berger for the latest episode of the “Cancer Horizons” podcast to discuss frontline treatment options for patients with metastatic triple-negative breast cancer. Berg...

31 Dec 202514min

S7 Ep1: The Importance of Spotting Endometrial Cancer

S7 Ep1: The Importance of Spotting Endometrial Cancer

Endometrial cancer is on the rise. Hear survivor Angélica and Eisai Inc.'s Teresa Cronin discuss the Spot Her® initiative, which empowers women to spot early signs. This episode is sponsored by Eisai.

18 Mars 202510min

S6 Ep23: ROS1+ Non-Small Cell Lung Cancer: Progress in Care

S6 Ep23: ROS1+ Non-Small Cell Lung Cancer: Progress in Care

17 Sep 202419min

S6 Ep22: Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

S6 Ep22: Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma. And finally, we’ll discuss another ca...

4 Mars 20247min

S6 Ep21: Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

S6 Ep21: Cannabis Talks During Cancer, Cardiometabolic Comorbidities and Current Research

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, an...

4 Mars 202410min

S6 Ep20: FDA Approvals from February 2024

S6 Ep20: FDA Approvals from February 2024

Last week, the Food and Drug Administration (FDA) approved four different therapies in the oncology space — one of which, Amtagvi, marks the first cellular therapy for the treatment of solid cancers. ...

23 Feb 20246min

S6 Ep19: Pancreatic Cancer Approval, Expert Discussion on Cancer Vaccine Development

S6 Ep19: Pancreatic Cancer Approval, Expert Discussion on Cancer Vaccine Development

Last week, we saw some FDA approvals for a new drug regimens, as well as some expert opinion about cancer vaccines. Additionally research touched upon the potential benefit of concurrent ctDNA and tum...

19 Feb 20249min

S6 Ep18: Guidelines for Childhood Neuroblastoma, FDA Decisions and More

S6 Ep18: Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews. Also last week, we covered researc...

12 Feb 20247min

Populärt inom Vetenskap

dumma-manniskor
p3-dystopia
allt-du-velat-veta
medicinvetarna
rss-ufobortom-rimligt-tvivel
svd-nyhetsartiklar
det-morka-psyket
kapitalet-en-podd-om-ekonomi
halsorevolutionen
bildningspodden
rss-vetenskapsradion
sexet
dumforklarat
rss-spraket
vetenskapsradion
rss-vetenskapsradion-2
4health-med-anna-sparre
rss-arkeologi-historia-podden-som-graver-i-vart-kulturlandskap
paranormalt-med-caroline-giertz
rss-ronden